Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.55 |
| ▸ | SLC40A1 | Q9NP59 | 7/20 | 0.55 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | NFKBIA | P25963 | 4/20 | 0.42 |
| ▸ | RELA | Q04206 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817307 | 0.86 | GABRA1 (0.61) | GABRA1PFKFB3SLC40A1PFKFB4CCKBR | |
| SCHEMBL13633768 | 0.83 | SLC40A1 (0.61) | PFKFB3SLC40A1NFKBIARELAMEN1 | |
| SCHEMBL13633883 | 0.82 | SLC40A1 (0.54) | PFKFB3SLC40A1NFKBIARELAMEN1 | |
| SCHEMBL13633919 | 0.78 | GABRA1 (0.72) | GABRA1PFKFB3PFKFB4CCKBRMMP8 | |
| SCHEMBL13633846 | 0.78 | SLC40A1 (0.58) | GABRA1PFKFB3SLC40A1PFKFB4CCKBR | |
| SCHEMBL13633765 | 0.78 | GABRA1 (0.56) | GABRA1PFKFB3SLC40A1PFKFB4CCKBR | |
| SCHEMBL13633824 | 0.77 | SLC40A1 (0.68) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL13633842 | 0.77 | NFKBIA (0.68) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL13633916 | 0.77 | SLC40A1 (0.72) | SLC40A1NFKBIARELAMEN1KMT2A | |
| SCHEMBL13211036 | 0.77 | GABRA1 (0.69) | GABRA1PFKFB3PFKFB4CCKBRMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | GABRA1 2865/4885PFKFB3 2356/4885SLC40A1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.